Brokers Offer Predictions for Invivyd FY2029 Earnings

Invivyd, Inc. (NASDAQ:IVVD) – HC Wainwright issued their FY2029 EPS estimates for Invivyd in a research note issued on Tuesday, February 4th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.41 for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share.

IVVD has been the topic of a number of other reports. D. Boral Capital restated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research report on Monday. Morgan Stanley lowered their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Invivyd has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Up 68.8 %

Invivyd stock opened at $2.11 on Wednesday. The business has a 50 day moving average price of $0.52 and a two-hundred day moving average price of $0.82. Invivyd has a 12 month low of $0.35 and a 12 month high of $5.10. The stock has a market cap of $252.40 million, a price-to-earnings ratio of -1.08 and a beta of 0.61.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 816,466 shares of company stock worth $423,214 over the last three months. Company insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Invivyd in the second quarter valued at approximately $421,000. Cubist Systematic Strategies LLC grew its holdings in Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock worth $148,000 after acquiring an additional 53,499 shares during the period. Finally, Barclays PLC raised its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.